<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="jco"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3020700/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020700/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Journal of Clinical Oncology"><meta name="citation_title" content="Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors"><meta name="citation_authors" content="James N. Ingle, Daniel J. Schaid, Paul E. Goss, Mohan Liu, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Gregory D. Jenkins, Anthony Batzler, Lois Shepherd, Joseph Pater, Liewei Wang, Matthew J. Ellis, Vered Stearns, Daniel C. Rohrer, Matthew P. Goetz, Kathleen I. Pritchard, David A. Flockhart, Yusuke Nakamura, Richard M. Weinshilboum"><meta name="citation_date" content="1 November 2010"><meta name="citation_issue" content="31"><meta name="citation_volume" content="28"><meta name="citation_firstpage" content="4674"><meta name="citation_doi" content="10.1200/JCO.2010.28.5064"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3020700/?report=abstract"><meta name="citation_pmid" content="20876420"><meta name="DC.Title" content="Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society of Clinical Oncology"><meta name="DC.Contributor" content="James N. Ingle"><meta name="DC.Contributor" content="Daniel J. Schaid"><meta name="DC.Contributor" content="Paul E. Goss"><meta name="DC.Contributor" content="Mohan Liu"><meta name="DC.Contributor" content="Taisei Mushiroda"><meta name="DC.Contributor" content="Judy-Anne W. Chapman"><meta name="DC.Contributor" content="Michiaki Kubo"><meta name="DC.Contributor" content="Gregory D. Jenkins"><meta name="DC.Contributor" content="Anthony Batzler"><meta name="DC.Contributor" content="Lois Shepherd"><meta name="DC.Contributor" content="Joseph Pater"><meta name="DC.Contributor" content="Liewei Wang"><meta name="DC.Contributor" content="Matthew J. Ellis"><meta name="DC.Contributor" content="Vered Stearns"><meta name="DC.Contributor" content="Daniel C. Rohrer"><meta name="DC.Contributor" content="Matthew P. Goetz"><meta name="DC.Contributor" content="Kathleen I. Pritchard"><meta name="DC.Contributor" content="David A. Flockhart"><meta name="DC.Contributor" content="Yusuke Nakamura"><meta name="DC.Contributor" content="Richard M. Weinshilboum"><meta name="DC.Date" content="2010 Nov 1"><meta name="DC.Identifier" content="10.1200/JCO.2010.28.5064"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors"><meta property="og:type" content="article"><meta property="og:description" content="We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.A nested ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020700/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-jco.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC3020700/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC3020700/pdf/zlj4674.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE88993EDD516BD10000000003B9025C.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-3"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3020700%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=%22J Clin Oncol%22[journal]" class="navlink">J Clin Oncol</a></li><li class="accid">PMC3020700</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-jco.gif" alt="Logo of jco" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,56,105,76" alt="Home" title="Home" href="http://jco.ascopubs.org" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="104,56,258,76" alt="This Article" title="This Article" href="http://jco.ascopubs.org/cgi/content/full/28/31/4674" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText" target="pmc_ext"><area shape="rect" coords="0,0,157,57" href="http://jco.ascopubs.org/" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="257,56,380,76" alt="Search" title="Search" href="http://jco.ascopubs.org/search.dtl" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="379,56,500,77" alt="Submit" title="Submit" href="http://submit.jco.org/" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="poly" coords="450,2,431,9,425,27,429,43,437,54,459,55,471,52,483,42,486,29,479,11,466,2,449,2" alt="ASCO JCO Homepage" title="ASCO JCO Homepage" href="http://jco.ascopubs.org" ref="reftype=publisher&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">J Clin Oncol</a></span>. 2010 Nov 1; 28(31): 4674–4682. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Sep 20. </span>  <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1200%2FJCO.2010.28.5064" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1200/JCO.2010.28.5064</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3020700</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20876420">20876420</a></div></div></div></div><h1 class="content-title">Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Ingle%20JN%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717716328160" co-class="co-affbox">James N. Ingle</a>,<sup></sup><sup></sup> <a href="/pubmed/?term=Schaid%20DJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717724219152" co-class="co-affbox">Daniel J. Schaid</a>,<sup></sup> <a href="/pubmed/?term=Goss%20PE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717723096752" co-class="co-affbox">Paul E. Goss</a>,<sup></sup> <a href="/pubmed/?term=Liu%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717723094656" co-class="co-affbox">Mohan Liu</a>,<sup></sup> <a href="/pubmed/?term=Mushiroda%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717720711456" co-class="co-affbox">Taisei Mushiroda</a>,<sup></sup> <a href="/pubmed/?term=Chapman%20JA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717720709360" co-class="co-affbox">Judy-Anne W. Chapman</a>,<sup></sup> <a href="/pubmed/?term=Kubo%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717706511488" co-class="co-affbox">Michiaki Kubo</a>,<sup></sup> <a href="/pubmed/?term=Jenkins%20GD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717706509392" co-class="co-affbox">Gregory D. Jenkins</a>,<sup></sup> <a href="/pubmed/?term=Batzler%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717715687552" co-class="co-affbox">Anthony Batzler</a>,<sup></sup> <a href="/pubmed/?term=Shepherd%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717725177184" co-class="co-affbox">Lois Shepherd</a>,<sup></sup> <a href="/pubmed/?term=Pater%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717725175088" co-class="co-affbox">Joseph Pater</a>,<sup></sup> <a href="/pubmed/?term=Wang%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717720924816" co-class="co-affbox">Liewei Wang</a>,<sup></sup> <a href="/pubmed/?term=Ellis%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717720922720" co-class="co-affbox">Matthew J. Ellis</a>,<sup></sup> <a href="/pubmed/?term=Stearns%20V%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717715800496" co-class="co-affbox">Vered Stearns</a>,<sup></sup> <a href="/pubmed/?term=Rohrer%20DC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717715798400" co-class="co-affbox">Daniel C. Rohrer</a>,<sup></sup> <a href="/pubmed/?term=Goetz%20MP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717716860064" co-class="co-affbox">Matthew P. Goetz</a>,<sup></sup> <a href="/pubmed/?term=Pritchard%20KI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717717386384" co-class="co-affbox">Kathleen I. Pritchard</a>,<sup></sup> <a href="/pubmed/?term=Flockhart%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717717384288" co-class="co-affbox">David A. Flockhart</a>,<sup></sup> <a href="/pubmed/?term=Nakamura%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717725162272" co-class="co-affbox">Yusuke Nakamura</a>,<sup></sup> and  <a href="/pubmed/?term=Weinshilboum%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420" class="affpopup" co-rid="_co_idm139717725160176" co-class="co-affbox">Richard M. Weinshilboum</a><sup></sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139717716328160"><h3 class="no_margin">James N. Ingle</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Ingle%20JN%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">James N. Ingle</a></div></div><div id="_co_idm139717724219152"><h3 class="no_margin">Daniel J. Schaid</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Schaid%20DJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Daniel J. Schaid</a></div></div><div id="_co_idm139717723096752"><h3 class="no_margin">Paul E. Goss</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Goss%20PE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Paul E. Goss</a></div></div><div id="_co_idm139717723094656"><h3 class="no_margin">Mohan Liu</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Liu%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Mohan Liu</a></div></div><div id="_co_idm139717720711456"><h3 class="no_margin">Taisei Mushiroda</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Mushiroda%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Taisei Mushiroda</a></div></div><div id="_co_idm139717720709360"><h3 class="no_margin">Judy-Anne W. Chapman</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Chapman%20JA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Judy-Anne W. Chapman</a></div></div><div id="_co_idm139717706511488"><h3 class="no_margin">Michiaki Kubo</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Kubo%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Michiaki Kubo</a></div></div><div id="_co_idm139717706509392"><h3 class="no_margin">Gregory D. Jenkins</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Jenkins%20GD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Gregory D. Jenkins</a></div></div><div id="_co_idm139717715687552"><h3 class="no_margin">Anthony Batzler</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Batzler%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Anthony Batzler</a></div></div><div id="_co_idm139717725177184"><h3 class="no_margin">Lois Shepherd</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Shepherd%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Lois Shepherd</a></div></div><div id="_co_idm139717725175088"><h3 class="no_margin">Joseph Pater</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Pater%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Joseph Pater</a></div></div><div id="_co_idm139717720924816"><h3 class="no_margin">Liewei Wang</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Wang%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Liewei Wang</a></div></div><div id="_co_idm139717720922720"><h3 class="no_margin">Matthew J. Ellis</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Ellis%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Matthew J. Ellis</a></div></div><div id="_co_idm139717715800496"><h3 class="no_margin">Vered Stearns</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Stearns%20V%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Vered Stearns</a></div></div><div id="_co_idm139717715798400"><h3 class="no_margin">Daniel C. Rohrer</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Rohrer%20DC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Daniel C. Rohrer</a></div></div><div id="_co_idm139717716860064"><h3 class="no_margin">Matthew P. Goetz</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Goetz%20MP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Matthew P. Goetz</a></div></div><div id="_co_idm139717717386384"><h3 class="no_margin">Kathleen I. Pritchard</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Pritchard%20KI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Kathleen I. Pritchard</a></div></div><div id="_co_idm139717717384288"><h3 class="no_margin">David A. Flockhart</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Flockhart%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">David A. Flockhart</a></div></div><div id="_co_idm139717725162272"><h3 class="no_margin">Yusuke Nakamura</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Nakamura%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Yusuke Nakamura</a></div></div><div id="_co_idm139717725160176"><h3 class="no_margin">Richard M. Weinshilboum</h3><p>From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</p><div>Find articles by <a href="/pubmed/?term=Weinshilboum%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20876420">Richard M. Weinshilboum</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139717714445696_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139717714445696_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139717714445696_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139717714445696_ai" style="display:none"><div class="fm-affl" id="aff1" lang="en">From the Mayo Clinic, Rochester, MN; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA; RIKEN Center for Genomic Medicine, Tokyo, Japan; NCIC Clinical Trials Group, Kingston; Sunnybrook Odette Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Washington University, St Louis, MO; Indiana University, Indianapolis, IN; Johns Hopkins School of Medicine, Baltimore, MD; and Ohio State University Medical Center, Columbus, OH.</div><div id="cor1">Corresponding author: James N. Ingle, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: <a href="mailto:dev@null" data-email="ude.oyam@semaj.elgni" class="oemail">ude.oyam@semaj.elgni</a>.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139717714445696_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Feb 18; Accepted 2010 Jul 9.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139717714445696_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> © 2010 by American Society of Clinical Oncology</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>See commentary "<a href="/pmc/articles/PMC4285377/">Scanning for Clues to Better Use Selective Estrogen Receptor
Modulators</a>" in <em>Cancer Discov</em>, volume 11 on&nbsp;page&nbsp;728.</div><div>See commentary "<a href="/pubmed/20876427" class="int-reflink">New pharmacogenomic paradigm in breast cancer treatment.</a>" in volume 28 on&nbsp;page&nbsp;4665.</div><div style="border-top: 1px solid rgb(102, 102, 153); margin: 5px 10% 3px;"></div><div>This article has been <a href="/pmc/articles/PMC3020700/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139717723262560" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139717723262560title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Purpose</h3><p id="__p1" class="p p-first-last">We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Patients and Methods</h3><p id="__p2" class="p p-first-last">A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Results</h3><p id="__p3" class="p p-first-last">The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest <em>P</em> values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (<em>TCL1A</em>) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression.</p></div><div id="__sec4" class="sec sec-last"><h3 id="__sec4title">Conclusion</h3><p id="__p4" class="p p-first-last">This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (<em>TCL1A</em>) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events.</p></div></div></div><div id="__sec5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec5title">INTRODUCTION</h2><p id="__p5" class="p p-first">The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole are established adjuvant therapies for postmenopausal women with early-stage breast cancer. This is based on multiple large, randomized clinical trials that have been conducted in the initial therapy setting<sup><a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467397">1</a>,<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467396">2</a></sup> after 2 to 3 years of tamoxifen<sup><a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467406">3</a>–<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467401">6</a></sup> and in the extended adjuvant therapy setting after about 5 years of tamoxifen.<sup><a href="#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467411">7</a>,<a href="#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467409">8</a></sup> An American Society of Clinical Oncology (ASCO) panel concluded that optimal adjuvant therapy for postmenopausal women with receptor-positive breast cancer includes an AI, either as initial therapy or after treatment with tamoxifen.<sup><a href="#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467394">9</a></sup> However, a substantial proportion of women are suboptimally adherent to anastrozole therapy,<sup><a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467417">10</a></sup> and about half of patients treated with AIs have joint-related complaints,<sup><a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467395">11</a>,<a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_221984837">12</a></sup> which likely contributes to decreased compliance.</p><p id="__p6" class="p p-last">MA.27 is a phase III trial comparing the nonsteroidal AI anastrozole with the steroidal AI exemestane as adjuvant therapy for early breast cancer. Musculoskeletal complaints were the most frequent reason given by patients on this trial for discontinuing therapy. We used a genome-wide association study (GWAS)<sup><a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467416">13</a></sup> to identify any SNP (single nucleotide polymorphism) associated with musculoskeletal adverse events (MS-AEs) in women receiving AI adjuvant therapy for early breast cancer, followed by studies of the possible functional basis for the associations.</p></div><div id="__sec6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec6title">PATIENTS AND METHODS</h2><div id="__sec7" class="sec sec-first"><h3 id="__sec7title">Source of Patients</h3><p id="__p7" class="p p-first">Cases and controls were obtained from the MA.27 trial conducted by the NCIC Clinical Trials Group (coordinating group), Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group (ECOG), North Central Cancer Treatment Group, Southwest Oncology Group, and International Breast Cancer Study Group (IBCSG). MA.27 included postmenopausal women with completely resected stages I to III breast cancer (American Joint Committee on Cancer [AJCC] Version 6) that was estrogen receptor (ER) positive and/or progesterone receptor positive. Patients were randomly assigned to 5 years of anastrozole or exemestane. This research was performed after approval by local institutional review boards in accordance with assurances filed with and approved by the Department of Health and Human Services.</p><p id="__p8" class="p p-last">Accrual of 6,827 North American patients occurred between May 2003 and July 2008, with the majority providing DNA and consent for genetic testing. Non–North American patients (n = 693) entered by the IBCSG did not contribute DNA. MA.27 initially included a second random assignment to celecoxib or placebo, but this was discontinued in December 2004 after the entry of 1,622 patients because of reports of cardiovascular toxicity associated with celecoxib.<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467402">14</a></sup></p></div><div id="__sec8" class="sec"><h3 id="__sec8title">Case Definition for MS-AEs</h3><p id="__p9" class="p p-first-last">Cases had at least one of the following six MS-AEs: joint pain, muscle pain, bone pain, arthritis, diminished joint function, or other musculoskeletal problems. Cases were required to either (1) have at least grade 3 toxicity, according to the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events v3.0, or (2) go off treatment for any grade of MS-AE within the first 2 years (ie, an MS-AE occurring after 2 years was not considered a case). Participants who fulfilled the case definition while on celecoxib or within 3 months after stopping celecoxib were excluded as cases.</p></div><div id="__sec9" class="sec"><h3 id="__sec9title">Control Definition</h3><p id="__p10" class="p p-first-last">Controls did not experience any of the MS-AEs, were followed for at least 2 years, and had at least 6 months longer follow-up than a case to which they were matched. This meant that all controls were off celecoxib for at least 6 months.</p></div><div id="__sec10" class="sec"><h3 id="__sec10title">Study Design</h3><p id="__p11" class="p p-first-last">A nested, matched case-control design was used, with matching on the following factors: treatment arm (exemestane, anastrozole), prior adjuvant chemotherapy (yes, no), age at start of AI treatment (± 5 years), celecoxib (yes, no), and time on study. When possible, each case was matched exactly with two controls. Otherwise, we used close matching based on a distance between each case and all potential controls determined with an optimal matching algorithm.<sup><a href="#B15" rid="B15" class=" bibr popnode">15</a></sup> The majority of MA.27 patients were white (94%), and this GWAS was restricted to white patients. Additional covariates evaluated were body mass index, bisphosphonate use (yes, no), fractures in past 10 years (yes, no), baseline ECOG performance status, prior hormone replacement therapy (HRT; yes, no), prior adjuvant radiotherapy (yes, no), and prior taxane (yes, no).</p></div><div id="__sec11" class="sec"><h3 id="__sec11title">Genotyping and Quality Control</h3><p id="__p12" class="p p-first-last">Two cases and two controls were randomly chosen as duplicates for quality control of genotype concordance. A white parent-child Centre d'Etude du Polymorphisme Humain (CEPH) trio from the HapMaP was included to check for Mendelian transmission of alleles. Genotypes were determined by the RIKEN Center for Genomic Medicine with the Illumina Human610-Quad BeadChip platform (Illumina, San Diego, CA).</p></div><div id="__sec12" class="sec"><h3 id="__sec12title">Statistical Analyses</h3><p id="__p13" class="p p-first">Primary analyses were based on conditional logistic regression to account for the matched design. SNP genotypes were coded as additive effects on the log odds ratio by coding as 0, 1, or 2 for the count of the minor allele. This resulted in a likelihood ratio test with 1 <em>df</em> for each SNP. The primary covariates used to match cases and controls were implicitly controlled in conditional logistic regression.</p><p id="__p14" class="p p-last">To avoid biases that might arise from differences in genetic ancestry (ie, population stratification), EIGENSTRAT software was used to determine eigenvalues for the SNP correlation matrix that statistically differed from zero on the basis of Tracy-Widom <em>P</em> values.<sup><a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467400">16</a>,<a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467405">17</a></sup> The corresponding eigenvectors were used as covariates in logistic regression models. We performed additional analyses to evaluate the robustness of our findings that are described in the Appendix (online only). Statistical analyses were conducted with the R statistical computing package, and SAS (SAS Institute, Cary, NC) and PLINK software.<sup><a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467399">18</a></sup></p></div><div id="__sec13" class="sec"><h3 id="__sec13title">Imputation and Fine Mapping</h3><p id="__p15" class="p p-first-last">SNPs were imputed within 300 kb on either side of the region containing the three SNPs with smallest <em>P</em> values on chromosome 14 using MACH 1.0 software,<sup><a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467407">19</a></sup> with the white CEPH European Ancestry (CEU) as the reference panel. A region (± 200 kb) around these same three SNPs was fine mapped at the RIKEN Center for Genomic Medicine. First, 29 SNPs were genotyped that were registered in the HapMaP database. After considering linkage disequilibrium (LD) among the SNPs, the strongest associated region of 20 kb (range, 95.23 to 95.25 Mb) was resequenced in 94 samples using an ABI3730 Genetic Analyzer (Applied Biosystems, Carlsbad, CA). From the 119 SNPs that were identified by resequencing, 16 additional SNPs with a minor allele frequency of 0.05 or more were genotyped using multiplex polymerase chain reaction–based Invader assay.</p></div><div id="__sec14" class="sec sec-last"><h3 id="__sec14title">Functional Genomic Studies</h3><p id="__p16" class="p p-first-last">The three genotyped SNPs on chromosome 14 with the smallest <em>P</em> values, as well as an imputed SNP with a small <em>P</em> value that was validated by fine mapping, were studied functionally using electrophoretic motility shift (EMS) assays, chromatin immunoprecipitation (ChIP) assays, determination of their relationship to TCLIA expression after estrogen exposure, and transfection studies. Details of the methods used to perform these functional assays are described in the Appendix.</p></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">RESULTS</h2><div id="__sec16" class="sec sec-first"><h3 id="__sec16title">Cases and Controls</h3><p id="__p17" class="p p-first-last">This analysis involved 293 cases and 585 controls which, including the duplicate samples and CEPH trios, had call rates of 0.982 to 0.999. Additional details are provided in the Appendix.</p></div><div id="__sec17" class="sec"><h3 id="__sec17title">Patient Characteristics</h3><p id="__p18" class="p p-first"><a href="/pmc/articles/PMC3020700/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> data show that the cases and controls were well balanced for most factors except prior HRT, which was significantly higher in cases (66% <em>v</em> 44%; <em>P</em> &lt; .001), and fractures within the past 10 years, which was also slightly higher in cases (13% <em>v</em> 9%; <em>P</em> = .06).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1.</h3><!--caption a7--><div class="caption"><p id="__p19">Patient Characteristics</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717714392240" class="xtable"><table frame="box" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="2" colspan="1" align="center">Characteristic</th><th colspan="2" rowspan="1" align="center">Cases(n = 293)<hr></th><th colspan="2" rowspan="1" align="center">Controls(n = 585)<hr></th><th rowspan="2" colspan="1" align="center">Wilcoxon Rank Sum <em>P</em></th><th rowspan="2" colspan="1" align="center">Fisher's Exact <em>P</em></th></tr><tr><th rowspan="1" colspan="1" align="center">No.</th><th rowspan="1" colspan="1" align="center">%</th><th rowspan="1" colspan="1" align="center">No.</th><th rowspan="1" colspan="1" align="center">%</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">Age, years</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Median</td><td colspan="2" rowspan="1" align="center">63.3</td><td colspan="2" rowspan="1" align="center">64.1</td><td rowspan="1" colspan="1" align="center">.61</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Q1</td><td colspan="2" rowspan="1" align="center">57.8</td><td colspan="2" rowspan="1" align="center">58.1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Q3</td><td colspan="2" rowspan="1" align="center">70.2</td><td colspan="2" rowspan="1" align="center">70.2</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Range</td><td colspan="2" rowspan="1" align="center">46.1-86.9</td><td colspan="2" rowspan="1" align="center">45.1-84.8</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Treatment arm (blinded)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    A</td><td rowspan="1" colspan="1" align="center">163</td><td rowspan="1" colspan="1" align="center">56</td><td rowspan="1" colspan="1" align="center">326</td><td rowspan="1" colspan="1" align="center">56</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.00</td></tr><tr><td rowspan="1" colspan="1" align="left">    B</td><td rowspan="1" colspan="1" align="center">130</td><td rowspan="1" colspan="1" align="center">44</td><td rowspan="1" colspan="1" align="center">259</td><td rowspan="1" colspan="1" align="center">44</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Celecoxib (blinded)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    C</td><td rowspan="1" colspan="1" align="center">221</td><td rowspan="1" colspan="1" align="center">75</td><td rowspan="1" colspan="1" align="center">426</td><td rowspan="1" colspan="1" align="center">73</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.42</td></tr><tr><td rowspan="1" colspan="1" align="left">    D</td><td rowspan="1" colspan="1" align="center">72</td><td rowspan="1" colspan="1" align="center">25</td><td rowspan="1" colspan="1" align="center">159</td><td rowspan="1" colspan="1" align="center">27</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Prior chemotherapy</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">200</td><td rowspan="1" colspan="1" align="center">68</td><td rowspan="1" colspan="1" align="center">405</td><td rowspan="1" colspan="1" align="center">69</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.82</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">93</td><td rowspan="1" colspan="1" align="center">32</td><td rowspan="1" colspan="1" align="center">180</td><td rowspan="1" colspan="1" align="center">31</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Prior taxane</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">244</td><td rowspan="1" colspan="1" align="center">84</td><td rowspan="1" colspan="1" align="center">490</td><td rowspan="1" colspan="1" align="center">84</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.92</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">48</td><td rowspan="1" colspan="1" align="center">16</td><td rowspan="1" colspan="1" align="center">94</td><td rowspan="1" colspan="1" align="center">16</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Unknown/missing</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Prior radiation therapy</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">100</td><td rowspan="1" colspan="1" align="center">34</td><td rowspan="1" colspan="1" align="center">175</td><td rowspan="1" colspan="1" align="center">30</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.22</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">192</td><td rowspan="1" colspan="1" align="center">66</td><td rowspan="1" colspan="1" align="center">407</td><td rowspan="1" colspan="1" align="center">70</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Unknown/missing</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Prior HRT</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">94</td><td rowspan="1" colspan="1" align="center">35</td><td rowspan="1" colspan="1" align="center">289</td><td rowspan="1" colspan="1" align="center">53</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">&lt; .001</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">178</td><td rowspan="1" colspan="1" align="center">65</td><td rowspan="1" colspan="1" align="center">258</td><td rowspan="1" colspan="1" align="center">47</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Unknown/missing</td><td rowspan="1" colspan="1" align="center">21</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">38</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Fracture in past 10 years</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">255</td><td rowspan="1" colspan="1" align="center">87</td><td rowspan="1" colspan="1" align="center">534</td><td rowspan="1" colspan="1" align="center">91</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.06</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">38</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1" align="center">51</td><td rowspan="1" colspan="1" align="center">9</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">BMI at baseline</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Missing</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">0.7</td><td rowspan="1" colspan="1" align="center">8</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Known</td><td rowspan="1" colspan="1" align="center">291</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">577</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Median</td><td colspan="2" rowspan="1" align="center">28.2</td><td colspan="2" rowspan="1" align="center">27.9</td><td rowspan="1" colspan="1" align="center">.51</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Q1</td><td colspan="2" rowspan="1" align="center">25.0</td><td colspan="2" rowspan="1" align="center">24.4</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Q3</td><td colspan="2" rowspan="1" align="center">33.1</td><td colspan="2" rowspan="1" align="center">32.4</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Range</td><td colspan="2" rowspan="1" align="center">17.7-56.8</td><td colspan="2" rowspan="1" align="center">16.9-50.8</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">ECOG PS at baseline</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    0</td><td rowspan="1" colspan="1" align="center">237</td><td rowspan="1" colspan="1" align="center">80.9</td><td rowspan="1" colspan="1" align="center">491</td><td rowspan="1" colspan="1" align="center">84</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.24</td></tr><tr><td rowspan="1" colspan="1" align="left">    1</td><td rowspan="1" colspan="1" align="center">55</td><td rowspan="1" colspan="1" align="center">18.8</td><td rowspan="1" colspan="1" align="center">88</td><td rowspan="1" colspan="1" align="center">15</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    2</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">0.3</td><td rowspan="1" colspan="1" align="center">6</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">Bisphosphonate use</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1" align="center">249</td><td rowspan="1" colspan="1" align="center">95</td><td rowspan="1" colspan="1" align="center">473</td><td rowspan="1" colspan="1" align="center">87</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.66</td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1" align="center">12</td><td rowspan="1" colspan="1" align="center">5</td><td rowspan="1" colspan="1" align="center">72</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Unknown/missing</td><td rowspan="1" colspan="1" align="center">10</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">40</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">MS-AEs withdrew from therapy</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Yes</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 1</td><td rowspan="1" colspan="1" align="center">17</td><td rowspan="1" colspan="1" align="center">6</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 2</td><td rowspan="1" colspan="1" align="center">108</td><td rowspan="1" colspan="1" align="center">37</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 3</td><td rowspan="1" colspan="1" align="center">101</td><td rowspan="1" colspan="1" align="center">34</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 4</td><td rowspan="1" colspan="1" align="center">6</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    No</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 3</td><td rowspan="1" colspan="1" align="center">58</td><td rowspan="1" colspan="1" align="center">20</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">        Grade 4</td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">0</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm139717714392240" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3020700/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm139717718876096"><p id="__p20" class="p p-first-last">Abbreviations: Q1, first quartile; Q3, third quartile; HRT, hormone replacement therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance status; MS-AE, musculoskeletal adverse event.</p></div></div></div></div><div id="__sec18" class="sec"><h3 id="__sec18title">MS-AEs</h3><p id="__p21" class="p p-first-last">The maximum grade MS-AEs are presented in <a href="/pmc/articles/PMC3020700/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> according to whether the patients discontinued AI therapy. Among the 293 cases, the number of days until the first MS-AE ranged from 10 to 726 (median, 223 days; mean, 276 days). The majority of cases had joint pain as their only MS-AE (184 cases; 62.8%) or in combination with other MS-AEs (56 cases; 19.1%).</p></div><div id="__sec19" class="sec"><h3 id="__sec19title">Genotyping Results</h3><p id="__p22" class="p p-first-last">In all, 592,236 SNPs were genotyped, but 11,281 (1.9%) were considered failures by the laboratory. Of these, 29,478 SNPs with a minor allele frequency (MAF) &lt; 0.01 were excluded because of limited power for association analyses. The exact test for Hardy-Weinberg equilibrium was performed in the controls. The quantile-quantile plot of these <em>P</em> values (Appendix Fig A1, online only) illustrates SNPs with a departure from Hardy-Weinberg equilibrium, and we excluded 82 SNPs with a <em>P</em> value &lt; 1E-06; sensitivity analyses were conducted with differing <em>P</em> value thresholds, and they did not affect the analysis (data not shown). Therefore 551,395 SNPs were used for the association analyses.</p></div><div id="__sec20" class="sec"><h3 id="__sec20title">Control for Potential Population Stratification</h3><p id="__p23" class="p p-first-last">To control for potential population stratification, SNPs were chosen that were uncorrelated with each other to avoid local genomic LD having undesirable impact on global genomic estimates of population stratification. SNPs were considered uncorrelated when the absolute value of the Pearson correlation was &lt; 0.063.<sup><a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467404">20</a>–<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467412">22</a></sup> This resulted in 7,077 SNPs being used in the EIGENSTRAT analyses. From these analyses, eight eigenvalues were identified with Tracy-Widom <em>P</em> values &lt; .05. None of the corresponding eight eigenvectors differed significantly (ie, all <em>P</em> &gt; .05) between cases and controls.</p></div><div id="__sec21" class="sec"><h3 id="__sec21title">GWAS Analyses: Cases Versus Controls</h3><p id="__p24" class="p p-first">By the conditional logistic regression analyses adjusted for population stratification, the smallest <em>P</em> value was 7.74E-07, close to the commonly accepted threshold for genome-wide significance of 1E-07. Adjusting for the eigenvectors had little influence on the results (see quantile-quantile plot for the conditional logistic regression results, both adjusted and unadjusted for the eigenvectors, in Appendix Fig A2, online only), which also illustrates that the variation inflation factor lambda in Devlin and Roeder<sup><a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467413">23</a></sup> is close to 1.0. The distribution of <em>P</em> values across the genome is illustrated in the Manhattan plot (<a href="/pmc/articles/PMC3020700/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig 1</span></a>A). The most striking <em>P</em> values (&lt; 1E-06) were for three SNPs on chromosome 14 (<a href="/pmc/articles/PMC3020700/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Adjusting for the eight eigenvectors, or additionally for prior history of fractures and HRT use, did not substantially alter our findings, nor did the results change substantially according to the unadjusted and unmatched Armitage <em>P</em> values (<a href="/pmc/articles/PMC3020700/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Exploratory analyses for possible SNP-SNP interactions and per allele differences between the two blinded treatment arms were all nonsignificant after adjusting for multiple testing.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC3020700/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717720619696" class="figure"><a href="/pmc/articles/PMC3020700/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650001.jpg"></a></div><div id="largeobj_idm139717720619696" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3020700/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC3020700/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig 1.</a></div><!--caption a7--><div class="caption"><p id="__p25">(A) Manhattan plot of –log10 (<em>P</em> values) from conditional logistic regression adjusted for eight eigenvectors versus chromosomal position of single nucleotide polymorphisms (SNPs). (B) Chromosome 14 region of interest: Manhattan plot of –log10 (<em>P</em> values) from conditional logistic regression adjusted for eight eigenvectors for observed (blue circle), imputed (black diamond), and fine mapped (red asterisk) SNP genotypes.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2.</h3><!--caption a7--><div class="caption"><p id="__p26">SNPs With Smallest <em>P</em> Values Identified by Genotyping</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717719654832" class="xtable"><table frame="box" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="2" colspan="1" align="center">SNP</th><th rowspan="2" colspan="1" align="center">Chromosome</th><th rowspan="2" colspan="1" align="center">Position (bp)</th><th colspan="2" rowspan="1" align="center">Minor Allele Frequency<hr></th><th rowspan="1" colspan="1" align="center">Unadjusted<sup>*</sup><hr></th><th rowspan="1" colspan="1" align="center">Armitage<hr></th><th colspan="4" rowspan="1" align="center">Adjusted for Eight Eigenvectors<sup>*</sup><hr></th></tr><tr><th rowspan="1" colspan="1" align="center">Cases</th><th rowspan="1" colspan="1" align="center">Controls</th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">OR</th><th rowspan="1" colspan="1" align="center">95% CI</th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center"><em>P</em><sup>†</sup></th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs7158782</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">95238884</td><td rowspan="1" colspan="1" align="center">0.189</td><td rowspan="1" colspan="1" align="center">0.109</td><td rowspan="1" colspan="1" align="center">3.48E-06</td><td rowspan="1" colspan="1" align="center">3.34E-06</td><td rowspan="1" colspan="1" align="center">2.13</td><td rowspan="1" colspan="1" align="center">1.58 to 2.87</td><td rowspan="1" colspan="1" align="center">7.74E-07</td><td rowspan="1" colspan="1" align="center">4.73E-07</td></tr><tr><td rowspan="1" colspan="1" align="left">rs7159713</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">95239330</td><td rowspan="1" colspan="1" align="center">0.189</td><td rowspan="1" colspan="1" align="center">0.109</td><td rowspan="1" colspan="1" align="center">3.48E-06</td><td rowspan="1" colspan="1" align="center">3.34E-06</td><td rowspan="1" colspan="1" align="center">2.13</td><td rowspan="1" colspan="1" align="center">1.58 to 2.87</td><td rowspan="1" colspan="1" align="center">7.74E-07</td><td rowspan="1" colspan="1" align="center">4.73E-07</td></tr><tr><td rowspan="1" colspan="1" align="left">rs2369049</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">95241604</td><td rowspan="1" colspan="1" align="center">0.176</td><td rowspan="1" colspan="1" align="center">0.100</td><td rowspan="1" colspan="1" align="center">9.17E-06</td><td rowspan="1" colspan="1" align="center">6.98E-06</td><td rowspan="1" colspan="1" align="center">2.08</td><td rowspan="1" colspan="1" align="center">1.54 to 2.83</td><td rowspan="1" colspan="1" align="center">2.23E-06</td><td rowspan="1" colspan="1" align="center">1.96E-06</td></tr><tr><td rowspan="1" colspan="1" align="left">rs4742490</td><td rowspan="1" colspan="1" align="center">9</td><td rowspan="1" colspan="1" align="center">8361609</td><td rowspan="1" colspan="1" align="center">0.375</td><td rowspan="1" colspan="1" align="center">0.277</td><td rowspan="1" colspan="1" align="center">4.41E-05</td><td rowspan="1" colspan="1" align="center">2.79E-05</td><td rowspan="1" colspan="1" align="center">1.65</td><td rowspan="1" colspan="1" align="center">1.31 to 2.08</td><td rowspan="1" colspan="1" align="center">2.04E-05</td><td rowspan="1" colspan="1" align="center">1.05E-03</td></tr><tr><td rowspan="1" colspan="1" align="left">rs6637820</td><td rowspan="1" colspan="1" align="center">23</td><td rowspan="1" colspan="1" align="center">130227989</td><td rowspan="1" colspan="1" align="center">0.123</td><td rowspan="1" colspan="1" align="center">0.062</td><td rowspan="1" colspan="1" align="center">1.35E-05</td><td rowspan="1" colspan="1" align="center">8.21E-06</td><td rowspan="1" colspan="1" align="center">2.28</td><td rowspan="1" colspan="1" align="center">1.55 to 3.37</td><td rowspan="1" colspan="1" align="center">2.93E-05</td><td rowspan="1" colspan="1" align="center">3.61E-05</td></tr><tr><td rowspan="1" colspan="1" align="left">rs1207405</td><td rowspan="1" colspan="1" align="center">22</td><td rowspan="1" colspan="1" align="center">24970849</td><td rowspan="1" colspan="1" align="center">0.111</td><td rowspan="1" colspan="1" align="center">0.058</td><td rowspan="1" colspan="1" align="center">6.84E-05</td><td rowspan="1" colspan="1" align="center">9.12E-05</td><td rowspan="1" colspan="1" align="center">2.28</td><td rowspan="1" colspan="1" align="center">1.54 to 3.38</td><td rowspan="1" colspan="1" align="center">3.76E-05</td><td rowspan="1" colspan="1" align="center">4.47E-04</td></tr><tr><td rowspan="1" colspan="1" align="left">rs17017756</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">79821583</td><td rowspan="1" colspan="1" align="center">0.140</td><td rowspan="1" colspan="1" align="center">0.218</td><td rowspan="1" colspan="1" align="center">1.28E-04</td><td rowspan="1" colspan="1" align="center">9.99E-05</td><td rowspan="1" colspan="1" align="center">0.55</td><td rowspan="1" colspan="1" align="center">0.42 to 0.74</td><td rowspan="1" colspan="1" align="center">4.97E-05</td><td rowspan="1" colspan="1" align="center">2.98E-05</td></tr><tr><td rowspan="1" colspan="1" align="left">rs260964</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">39330359</td><td rowspan="1" colspan="1" align="center">0.352</td><td rowspan="1" colspan="1" align="center">0.259</td><td rowspan="1" colspan="1" align="center">7.97E-05</td><td rowspan="1" colspan="1" align="center">5.85E-05</td><td rowspan="1" colspan="1" align="center">1.60</td><td rowspan="1" colspan="1" align="center">1.27 to 2.01</td><td rowspan="1" colspan="1" align="center">5.70E-05</td><td rowspan="1" colspan="1" align="center">8.32E-06</td></tr><tr><td rowspan="1" colspan="1" align="left">rs409228</td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1" align="center">41040417</td><td rowspan="1" colspan="1" align="center">0.230</td><td rowspan="1" colspan="1" align="center">0.321</td><td rowspan="1" colspan="1" align="center">6.25E-05</td><td rowspan="1" colspan="1" align="center">5.59E-05</td><td rowspan="1" colspan="1" align="center">0.61</td><td rowspan="1" colspan="1" align="center">0.48 to 0.78</td><td rowspan="1" colspan="1" align="center">5.89E-05</td><td rowspan="1" colspan="1" align="center">5.44E-05</td></tr><tr><td rowspan="1" colspan="1" align="left">rs12186280</td><td rowspan="1" colspan="1" align="center">4</td><td rowspan="1" colspan="1" align="center">108046724</td><td rowspan="1" colspan="1" align="center">0.102</td><td rowspan="1" colspan="1" align="center">0.052</td><td rowspan="1" colspan="1" align="center">8.87E-05</td><td rowspan="1" colspan="1" align="center">8.63E-05</td><td rowspan="1" colspan="1" align="center">2.24</td><td rowspan="1" colspan="1" align="center">1.51 to 3.32</td><td rowspan="1" colspan="1" align="center">6.22E-05</td><td rowspan="1" colspan="1" align="center">3.68E-04</td></tr><tr><td rowspan="1" colspan="1" align="left">rs6633380</td><td rowspan="1" colspan="1" align="center">23</td><td rowspan="1" colspan="1" align="center">13756099</td><td rowspan="1" colspan="1" align="center">0.296</td><td rowspan="1" colspan="1" align="center">0.212</td><td rowspan="1" colspan="1" align="center">1.28E-04</td><td rowspan="1" colspan="1" align="center">6.63E-05</td><td rowspan="1" colspan="1" align="center">1.65</td><td rowspan="1" colspan="1" align="center">1.29 to 2.10</td><td rowspan="1" colspan="1" align="center">6.88E-05</td><td rowspan="1" colspan="1" align="center">3.93E-05</td></tr><tr><td rowspan="1" colspan="1" align="left">rs2515034</td><td rowspan="1" colspan="1" align="center">8</td><td rowspan="1" colspan="1" align="center">119565108</td><td rowspan="1" colspan="1" align="center">0.092</td><td rowspan="1" colspan="1" align="center">0.044</td><td rowspan="1" colspan="1" align="center">1.04E-04</td><td rowspan="1" colspan="1" align="center">7.31E-05</td><td rowspan="1" colspan="1" align="center">2.34</td><td rowspan="1" colspan="1" align="center">1.54 to 3.57</td><td rowspan="1" colspan="1" align="center">8.53E-05</td><td rowspan="1" colspan="1" align="center">5.04E-04</td></tr><tr><td rowspan="1" colspan="1" align="left">rs11145462</td><td rowspan="1" colspan="1" align="center">9</td><td rowspan="1" colspan="1" align="center">79332930</td><td rowspan="1" colspan="1" align="center">0.399</td><td rowspan="1" colspan="1" align="center">0.491</td><td rowspan="1" colspan="1" align="center">1.80E-04</td><td rowspan="1" colspan="1" align="center">2.10E-04</td><td rowspan="1" colspan="1" align="center">0.65</td><td rowspan="1" colspan="1" align="center">0.53 to 0.81</td><td rowspan="1" colspan="1" align="center">8.19E-05</td><td rowspan="1" colspan="1" align="center">1.99E-04</td></tr><tr><td rowspan="1" colspan="1" align="left">rs4246309</td><td rowspan="1" colspan="1" align="center">15</td><td rowspan="1" colspan="1" align="center">98584524</td><td rowspan="1" colspan="1" align="center">0.447</td><td rowspan="1" colspan="1" align="center">0.347</td><td rowspan="1" colspan="1" align="center">6.66E-05</td><td rowspan="1" colspan="1" align="center">5.07E-05</td><td rowspan="1" colspan="1" align="center">1.52</td><td rowspan="1" colspan="1" align="center">1.23 to 1.88</td><td rowspan="1" colspan="1" align="center">8.81E-05</td><td rowspan="1" colspan="1" align="center">1.39E-04</td></tr></tbody></table></div><div id="largeobj_idm139717719654832" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3020700/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm139717717526784"><p id="__p27" class="p p-first-last">Abbreviations: SNP, single nucleotide polymorphism; bp, base pair; OR, odds ratio.</p></div><div id="TF2-1"><sup>*</sup>Conditional logistic regression.</div><div id="TF2-2"><sup>†</sup>Prior history of fractures and hormone usage.</div></div></div></div><div id="__sec22" class="sec"><h3 id="__sec22title">Imputation and Fine Mapping</h3><p id="__p30" class="p p-first-last">Imputing SNPs within 300 kb of the smallest <em>P</em> value SNPs on chromosome 14, illustrated in <a href="/pmc/articles/PMC3020700/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>B, showed that rs7159713 and rs2369049 were in LD with rs7158782 (Pearson correlation of minor allele dosage &gt; 0.8) and that an additional imputed SNP (rs11849538) also showed an association with MS-AEs (MAF cases/controls: 0.172/0.091; odds ratio, 2.21; <em>P</em> = 6.67E-07). Using the imputed data, we focused on a 200-kb region and genotyped 29 SNPs, including the imputed SNP (rs11849538), which was verified by this genotyping and the DNA sequencing. We examined the LD block of the candidate region and focused on the strongest associated region of 20 kb (95.23 to 95.25 Mb), which included four SNPs (rs7158782, rs7159713, rs2369049, and rs11849538). We resequenced this region and identified a total of 119 SNPs that included 49 novel SNPs and 70 SNPs already registered in the dbSNP database. Hence, we genotyped 16 additional SNPs with MAFs of 0.05 or greater, but no SNP showed a stronger association than rs11849538. Therefore, we concluded that rs11849538 or the other three highly linked SNPs (rs7158782, rs7159713, and rs2369049) might have functional significance.</p></div><div id="__sec23" class="sec sec-last"><h3 id="__sec23title">Functional Genomic Studies of SNPs on Chromosome 14</h3><p id="__p31" class="p p-first">The three genotyped SNPs (rs7158782, rs7159713, and rs2369049) and the imputed SNP (rs11849538) were all close to the T-cell leukemia 1A (<em>TCL1A</em>) gene (<a href="/pmc/articles/PMC3020700/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig 2</span></a>). All four of these SNPs were in LD (<em>R</em><sup>2</sup> &gt; 0.85). We attempted to determine whether any of these SNPs might be functional on the basis of EMS or ChIP assays, and if they were, whether they might be associated with variation in the expression of the closest gene, <em>TCL1A</em>; whether estrogens might play a role in their functional effects; and, finally, whether <em>TCL1A</em> might influence the expression of receptors or cytokines known to play a role in arthritis.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC3020700/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717725394944" class="figure"><a href="/pmc/articles/PMC3020700/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650002.jpg"></a></div><div id="largeobj_idm139717725394944" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3020700/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC3020700/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Fig 2.</a></div><!--caption a7--><div class="caption"><p id="__p32">Single nucleotide polymorphisms identified on chromosome 14 (Chr 14), their relationship to T-cell leukemia (TCL) genes, and linkage disequilibrium relationships. bp, base pair.</p></div></div></div><p id="__p33">We first determined that <em>TCL1A</em> is highly and variably expressed in 288 lymphoblastoid cell lines from three different ethnic groups for which we have expression array data as well as genome-wide SNP data. EMS assays performed with lymphoblastoid cell nuclear extract showed a shift (ie, protein binding) for all but the rs2369049 SNP, with less binding by the variant than by the wild type (WT) sequences in all cases (Appendix Figs 3A to 3C, online only). The TRANSFAC database predicted that rs7158782 would disrupt a GATA-1 binding motif, and this prediction was supported by a ChIP assay (Appendix Fig 3C). However, of particular importance for this study, the TRANSFAC database also predicted that the SNP closest to the 3′ end of <em>TCL1A</em>—rs11849538—would create an estrogen response element (ERE), and this prediction was supported by the results of a ChIP assay (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig 3</span></a>C) performed using ERα-transfected lymphoblastoid cells with known genotype for the rs11849538 SNP. We then determined whether TCL1A expression might be estrogen dependent by exposing U20S cells stably transfected with ERα or ERβ to 0.1 nmol/L 17-β-estradiol (E2) and found eight- and six-fold increases in TCL1A mRNA expression after 18 hours and 1 hour, respectively (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figs 3</span></a>A and <a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -1.5em;">and3B),</span></span><span>3</span></a>B), linking TCL1A expression to estrogens.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717725591312" class="figure"><a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650003.jpg"></a></div><div id="largeobj_idm139717725591312" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3020700/figure/F3/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC3020700/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Fig 3.</a></div><!--caption a7--><div class="caption"><p id="__p34">(A) Relative T-cell leukemia 1A (TCL1A) expression in U2OS cells transfected with estrogen receptor alpha (ERα) exposed to 0.1 nmol (nM)/L 17-β-estradiol over 24 hours. (B) Relative TCL1A expression in U2OS cells transfected with ER beta (ERβ) exposed to 0.1 nmol/L 17-β-estradiol over 24 hours. (C) Chromatin immunoprecipitation assay using ERα-transfected lymphoblastoid cells with known genotype for the rs11849538 single nucleotide polymorphism (SNP). DNA ladder 1 (LAD1) and DNA ladder 2 (LAD2) are both Invitrogen (Carlsbad, CA) 1-kb DNA ladders, with LAD2 being a 1-kb Plus DNA ladder. Lanes 2 to 5 are polymerase chain reaction (PCR) products from DNA that was bound to human ERα antibody (Ab). The inputs for the variant (V) and wild type (WT) were PCR amplification products of pools of sheared DNA from the entire genome. (D) SNP-related differences in TCL1A expression and estrogen response in nine V (rs11849538) and nine WT lymphoblastoid cell lines transfected with ERα. (*) <em>P</em> &lt; .05. (†) <em>P</em> &lt; .01.</p></div></div></div><p id="__p35">We then determined the effect of different genotypes at these four SNPs on the estrogen-dependent TCL1A expression. To do that, we transiently transfected lymphoblastoid cell lines with known genotypes for the four SNPs with ERα, exposed the cell lines to various concentrations of E2, and determined the relationship of the SNPs to TCL1A expression (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig 3</span></a>D). In all three ethnic groups, the cells with the variant sequences—sequences that created an ERE at rs11849538—showed greater TCL1A expression than did those with the WT sequence.</p><p id="__p36" class="p">Finally, we knew that interleukin 17 (IL17) and the IL17 receptor A (IL17RA) were both therapeutic targets in patients with rheumatoid arthritis,<sup><a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467410">24</a></sup> so we determined whether the expression of TCL1A was correlated with the expression of either IL17 or IL17RA in the same 288 lymphoblastoid cell lines. Expression of TCL1A and IL7RA were correlated (<em>r</em> = 0.36; <em>P</em> &lt; 1.9E-10). We then demonstrated in U2OS cells that small interfering RNA knockdown of TCL1A resulted in decreased expression of IL17RA but increased expression of IL17 mRNA (<a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figs 4</span></a>A and <a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -1.5em;">and4B),</span></span><span>4</span></a>B), while overexpression of TCL1A resulted in increased IL17RA expression and decreased expression of mRNA for the ligand IL17 (<a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figs 4</span></a>C and <a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -1.5em;">and4</span></span><span>4</span></a>D).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717716660112" class="figure"><a href="/pmc/articles/PMC3020700/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650004.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650004.jpg"></a></div><div id="largeobj_idm139717716660112" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3020700/figure/F4/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC3020700/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Fig 4.</a></div><!--caption a7--><div class="caption"><p id="__p37">T-cell leukemia 1A (TCL1A), interleukin 17 receptor A (IL17RA), and interleukin 17 (IL17) mRNA levels after TCL1A small interfering RNA (siRNA) knockdown in (A) U2OS–estrogen receptor alpha (ERα) cells and (B) U2OS–ER beta (ERβ) after transient overexpression (OE) of TCL1A in (C) U2OS-ERα cells and (D) U2OS-ERβ cells. (*) <em>P</em> &lt; .05. (†) <em>P</em> &lt; .01. (‡) <em>P</em> &lt; .001.</p></div></div></div></div></div><div id="__sec24" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec24title">DISCUSSION</h2><p id="__p38" class="p p-first">This genome-wide nested case-control study identified four SNPs in tight LD on chromosome 14 that were associated with MS-AEs in women receiving AIs for resected early-stage breast cancer, with <em>P</em> values that ranged from 2.23E-06 to 6.67E-07, close to the Bonferroni threshold of 1E-07. The closest gene to these SNPs was <em>TCL1A</em> with the SNP having the smallest <em>P</em> value (rs11849538) located only 926 bp from the 3′ end of that gene.</p><p id="__p39">The significant advantages of our study design are that it avoids selection biases and exposure recall biases among cases, maximizes representativeness of controls, optimizes measurement of exposure (randomized treatment allocation), and ensures unbiased follow-up of all participants in a protocol-specified manner. In fact, our study design can be viewed as being strong as a cohort study but much more efficient.<sup><a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467403">25</a></sup> There are, however, general limitations of all GWASs,<sup><a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467398">26</a></sup> including the potential for false-positive associations, that underscore the requirement for replication. There were imbalances between cases and controls in terms of HRT and prior fractures, but these did not confound our findings. We recognize that the NCI criteria used to measure MS-AEs can be somewhat subjective, possibly with heterogeneous causes that could reduce power, but this does not have an impact on our findings. Additionally, our functional genomic studies are sufficiently compelling to justify further research.</p><p id="__p40">The purpose of this study was both to identify genetic markers for MS-AEs and to explore mechanisms that might be related to this drug-related AE in women exposed to AI-dependent decreased estrogen levels. Therefore, we examined functional characteristics of the SNPs as they might relate to estrogen action. It was striking that the SNP with the smallest <em>P</em> value (rs11849538) created an ERE shown by ChIP assay to be functional (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig 3</span></a>C). We determined whether estrogens and/or the SNPs might be functionally related to <em>TCL1A</em> and we demonstrated an eight-fold induction of TCL1A expression by 24 hours in ERα-transfected cells (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig 3</span></a>A) and significantly higher TCL1A expression after exposure to varying concentrations of E2 in lymphoblastoid cell lines containing the variant SNPs when compared with cells having the WT sequence after transient transfection with ERα (Fig 3D).</p><p id="__p41">TCL1A expression has previously been associated with a number of hematopoietic malignancies, including T-cell and B-cell lymphomas,<sup><a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467393">27</a></sup> and has been shown to enhance Akt serine threonine kinase activity, thus functioning as an Akt coactivator.<sup><a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467408">28</a></sup> TCL1A expression is thought to be restricted to early developmental cells of the immune system, including CD4<sup>−</sup>, CD8<sup>−</sup>, and CD3<sup>−</sup> thymocytes.<sup><a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_207467414">28</a></sup> However, there were no previous reports of the regulation of <em>TCL1A</em> by estrogen or of an association of TCL1A expression with cytokine receptor expression. Patients who carry the SNP variant identified in our GWAS that creates an ERE (rs11849538) might be more responsive to a given level of estrogen and thus display higher levels of TCL1A expression for any given level of estrogen (<a href="/pmc/articles/PMC3020700/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig 3</span></a>D). A reduction in estrogen levels during AI therapy might result in proportionally greater reductions in TCL1A expression in women with these SNPs than in women with the WT sequence. The mechanism by which differential changes in TCL1A expression might induce MS-AEs remains to be determined, but our observations with regard to its relationship to IL17RA expression indicate that the association of TCL1A expression with cytokine function is worthy of further exploration in the course of future studies.</p><p id="__p42">Finally, it is intriguing to speculate that our findings in women receiving AIs who develop MS-AEs may provide insight into the “arthritis of the menopause” described by Cecil and Archer 85 years ago.<sup><a href="#B29" rid="B29" class=" bibr popnode">29</a></sup> AI therapy might be considered an estrogen-deprivation stress test that could provide novel insights into symptoms related to estrogen deprivation that occur during menopause—74% of women without breast cancer in the Women's Health Initiative clinical trials reported joint pain.<sup><a href="#B30" rid="B30" class=" bibr popnode">30</a></sup></p><p id="__p43" class="p p-last">In summary, this GWAS identified four SNPs on chromosome 14 that were related to MS-AEs in patients receiving AI adjuvant therapy. The combination of four strong SNP signals and the equally strong functional linkage of these SNPs to AI effect focused our attention on these polymorphisms as possible biomarkers for risk for this important adverse drug reaction, on <em>TCL1A</em> as the potential link, and on cytokines as potential mechanistic factors. The determination of the mechanism of these MS-AEs would enable a focused approach to amelioration of symptoms, thus facilitating compliance and improving the benefits of AIs for women with early breast cancer.</p></div><div id="idm139717718861280" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139717718861280title">Acknowledgment</h2><div class="sec"><p id="__p49">We acknowledge the women who participated in the MA.27 clinical trial and provided DNA and consent for its use in genetic studies.</p></div></div><div id="idm139717724184432" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139717724184432title">Glossary Terms</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td id="G1">Estrogen response element (ERE):</td><td>Specific DNA sequences with high affinity for the estrogen receptor that are involved in gene expression in response to estradiol.</td></tr><tr><td id="G2">Genome-wide association study (GWAS):</td><td>Hypothesis-free studies that evaluate the association of genetic variations throughout the entire genome with traits, using high throughput genotyping technologies to assay SNPs.</td></tr><tr><td id="G3">Genotyping:</td><td>The process used for obtaining the genotype of a given gene or a genetic marker. Typically, polymerase chain reaction-based methods are used. However, in the case of single nucleotide polymorphism genotyping, microarray platforms are used routinely. Genotyping data serves several purposes, including a means to determine genetic diversity, to identify important genetic traits and in forensic and population studies. It is used increasingly in determining paternity of offspring. From a somatic point of view (within a tumor), genotyping is used to determine loss of heterozygosity.</td></tr><tr><td id="G4">HapMaP:</td><td>An international project that created a publically available genome-wide database of common human sequence variations, <a href="http://hapmap.ncbi.nlm.nih.gov" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://hapmap.ncbi.nlm.nih.gov</a>.</td></tr><tr><td id="G5">Hardy-Weinberg equilibrium:</td><td>A state in which genotype frequencies and ratios remain constant from generation to generation and in which genotype frequencies are a product of allele frequencies. A randomly mating population tends toward a Hardy-Weinberg equilibrium state if there are no mutations, migrations, or environmental factors favoring particular genotypes.</td></tr><tr><td id="G6">Imputation:</td><td>In a GWAS, the use of a reference data set (eg, HapMaP) and linkage disequilibrium in a region to infer the alleles of SNPs not directly genotyped.</td></tr><tr><td id="G7">Linkage disequilibrium:</td><td>Nonrandom association of linked genes. This is the tendency of the alleles of two separate but already linked loci to be found together more frequently than would be expected by chance alone.</td></tr><tr><td id="G8">Manhattan plot:</td><td>In a GWAS, the display of negative log (P values) on the Y-axis for SNPs across the 22 autosomes and sex chromosomes on the X-axis. The higher the point lies on the Y-axis, the lower the P value and the greater the significance.</td></tr><tr><td id="G9">Population stratification:</td><td>Differences in the allele frequencies in populations due to differences in ancestry.</td></tr><tr><td id="G10">SNP (single nucleotide polymorphism):</td><td>Genetic polymorphisms are natural variations in the genomic DNA sequence present in greater than 1% of the population, with SNP representing DNA variations in a single nucleotide. SNPs are being widely used to better understand disease processes, thereby paving the way for genetic-based diagnostics and therapeutics.</td></tr></tbody></table></div></div></div><div id="app1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="app1title">Appendix</h2><!--/article/back/app-group/app/--><div id="__sec27" class="sec sec-first"><div id="__sec28" class="sec sec-first"><p></p><h4 id="__sec28title" class="inline">Methods </h4><div id="__sec29" class="sec sec-first-last"><p></p><h5 id="__sec29title" class="inline">Identification of cases and controls. </h5><p id="__p70" class="p p-first-last">A total of 297 cases were identified. Matching resulted in 291 cases with two perfectly matched controls, four cases with one perfectly matched control, and one close control (allowing ± 10 years in three controls and eliminating the need to match on prior chemotherapy in one control). One case had two close controls after permitting age matching ± 10 years and one case had no matched controls. In addition, one control was excluded after review revealed that her control status was not valid. This resulted in 888 eligible patients (297 cases and 591 controls). However, four controls were not plated and, after genotyping, six samples (four cases and two controls) had call rates &lt; 98% and were excluded from analyses. This resulted in 293 cases and 585 controls.</p></div></div><div id="__sec30" class="sec"><p></p><h4 id="__sec30title" class="inline">Functional Genomic Studies </h4><div id="__sec31" class="sec sec-first"><p></p><h5 id="__sec31title" class="inline">Electrophoretic motility shift (EMS) assays. </h5><p id="__p71" class="p p-first">Nuclear extracts were prepared from cultured lymphoblastoid cells. The cells were pelleted by centrifugation at 1,500 × <em>g</em> for 2 minutes. The pellets were suspended in 400 μL of ice-cold hypotonic buffer A (10 mmol/L HEPES pH 7.9, 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L ethyleneglycoltetracetic acid [EGTA], 0.4% NP-40, 0.5 mmol/L phenylmethylsulfonylfluoride [(PMSF], and 0.5 mmol/L dithiothreitol [DTT]) and were incubated on ice for 15 minutes. The cell suspensions were then precipitated by centrifugation at 14,000 × <em>g</em> for 30 seconds, and the pellets were resuspended in 200 μL of buffer B (20 mmol/L HEPES pH 7.9, 400 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.5 mmol/L PMSF, and 1 mmol/L DTT), followed by shaking for 15 minutes at 4°C. After centrifugation, the supernatants were stored in aliquots at −70°C. The quantity of protein in the nuclear extracts was determined using the micro bicinchoninic acid protein assay (Pierce, Rockford, IL).</p><p id="__p72" class="p p-last">DNA/protein reactions and EMS assays were performed by using 10 μg of lymphoblastoid cell nuclear extract protein incubated with 1× binding buffer, 2.5% glycerol, 5 mmol/L MgCl<sub>2</sub>, 50 μg/μL Poly (dI·dT), 0.05% NP-40 (Pierce), and 10 fmol biotin 5′-labeled probes (IDT Integrated DNA Technologies, Coralville, IA) at room temperature for 20 minutes. In the same preparation, 2 pmol of unlabeled double-stranded probe was added as competitor before addition of the biotin-labeled probe for the competition studies. Samples were loaded on 6% Tris-borate-EDTA (TBE) gels and were run at 100 V for 1 hour in 0.5× TBE buffer.</p></div><div id="__sec32" class="sec"><p></p><h5 id="__sec32title" class="inline">ChIP assays. </h5><p id="__p73" class="p p-first-last">Chromatin immunoprecipitation (ChIP) assays were performed using the ChampionChIP one-day kit (SABiosciences, Frederick, MD). Polymerase chain reaction (PCR) was used to monitor the ChIP assay results. PCR reactions contained 1.25 units of Taq polymerase enzyme (Promega, Madison, WI), 1× reaction buffer, 1.5 mmol/L MgCl<sub>2</sub>, 0.5 mmol/L deoxyribonucleotide triphosphate (dNTP; Invitrogen, Carlsbad, CA), and 357 nmol/L each primer; a 2-μL amount of DNA from the ChIP assay was added in a final volume of 50 μL. In all, 20 μL of the PCR products were loaded on 1.2% agarose gel and were run at 100 V for 1.5 hours in 1× TAE buffer (Tris-acetic acid-EDTA).</p></div><div id="__sec33" class="sec"><p></p><h5 id="__sec33title" class="inline">Cell culture studies. </h5><p id="__p74" class="p p-first">The human U2OS–estrogen receptor alpha (ERα) and U2OS–ER beta (ERβ) cell lines were engineered by using the U2OS human osteosarcoma cell line with the T-REx System (Invitrogen), which allows control of the expression of the transgene by using doxycline (Dox) as an inducer. These cells were stably transfected with ERα and ERβ constructs in the laboratory of Thomas Spelsberg, PhD, at the Mayo Clinic (he generously provided the cells used in these studies). John Hawse, PhD, of the Mayo Clinic, provided consultative input.</p><p id="__p75" class="p p-last">For the experiments described in this study, human U2OS-ERα and U2OS-ERβ cell lines were cultured in six-well plates at a cell density of 60% in DMEM containing 10% (vol/vol) fetal bovine serum (FBS). Twenty-four hours later, the cells were transferred to DMEM containing 5% charcoal stripped serum for an additional 24 hours, followed by incubation in DMEM containing 100 ng/mL Dox. The cells were then cultured in DMEM with 100 ng/mL Dox plus 0.1 nmol/L 17-β-estradiol (E2) for 0, 0.5, 1, 2, 6, 10, 16, and 24 hours. Total RNA was then isolated from the cells with the RNeasy mini kit (Qiagen, Chatsworth, CA). One hundred nanograms of total RNA was used to perform quantitative reverse transcriptase PCR (qRT-PCR) with <em>TCL1A</em> primers (Qiagen) and β-actin primers (Qiagen) as controls.</p></div><div id="__sec34" class="sec"><p></p><h5 id="__sec34title" class="inline">Lymphoblastoid cell line transfection and estrogen exposure. </h5><p id="__p76" class="p p-first">Three cell lines with variant genotypes for the four chromosome 14 single nucleotide polymorphisms (SNPs) and three cell lines with the wild-type (WT) sequence from each of three ethnic groups (African American, European American, and Han Chinese American; a total of 18 individual cell lines), were cultured in RPMI-1640 media containing 15% (vol/vol) FBS. The genotypes for all four SNPs in each cell line were confirmed by PCR.</p><p id="__p77">The 18 cell lines were transiently transfected with a pcDNA4-ERα construct that was kindly provided by Dr. Spelsberg. For each cell line, 2 × 10<sup>6</sup> cells were suspended in the Cell Line Nucleofector Kit V (Lonza, Cologne, Germany) with 2 μg purified pcDNA4-ERα, and the cells were transfected with the Amaxa apparatus (Amaxa Biosystem, Cologne, Germany) using the T-030 program. For each cell line, cells from six electroporation procedures were pooled to obtain an adequate number of cells for use in the proposed experiments (ie, 12 × 10<sup>6</sup> cells per experiment).</p><p id="__p78" class="p p-last">Electroporated cells were then plated in RPMI-1640 medium supplemented with 15% FBS and were allowed to recover from the electroporation process for 48 hours. The transiently transfected cells were then cultured in six-well plates with RPMI-1640 media containing 5% (vol/vol) charcoal stripped serum for an additional 24 hours, followed by incubation in the same media containing 0, 0.00001, 0.0001, 0.001, 0.01, 0.1, 1, or 10 nmol/L E2 for 24 hours. Total RNA was then isolated from the cells with the RNeasy mini kit (Qiagen). Two hundred nanograms of total RNA was used to perform qRT-PCR with <em>TCL1A</em> and with ERα primers (Qiagen). The expression of TCL1A was corrected on the basis of ERα expression.</p></div><div id="__sec35" class="sec sec-last"><p></p><h5 id="__sec35title" class="inline"><em>TCL1A</em> transfection. </h5><p id="__p79" class="p p-first-last">U2OS-ERα and U2OS-ERβ cells were plated in a six-well tissue culture plate at a density of 500,000 cells per well in DMEM with 15% FBS for 24 hours at 37°C. Cells were transfected with 50 nmol/L TCL1A small interfering RNA (siRNA) or negative control siRNA (Qiagen) for <em>TCL1A</em> knockdown using Lipofectamine RNAiMAX (Invitrogen). Overexpression studies used FuGENE 6 (Roche, Indianapolis, IN). After 24 hours at 37°C, the medium was removed from the cells and replaced for an additional 24 hours with DMEM containing 10% FBS. mRNA was extracted using RNA Mini Kit (Qiagen) for qRT-PCR assay.</p></div></div><div id="__sec36" class="sec sec-last"><p></p><h4 id="__sec36title" class="inline">Supplemental Statistical Analyses </h4><p id="__p80" class="p p-first">Additional analyses were conducted to evaluate the robustness of our findings with respect to population stratification. First, we evaluated whether any of the nonmatching investigational covariates were significantly associated with musculoskeletal adverse events (MS-AEs) by using forward stepwise conditional logistic regression. Any factors that were statistically associated with an MS-AE (<em>P</em> &lt; .05) were also evaluated as adjusting covariates. Second, we performed conditional logistic regression but without any adjusting covariates to determine the influence of covariates. Third, we performed the usual Armitage test for trend, which ignores the matching and the covariates. Because several cases did not have matched controls and vice versa, the Armitage test for trend included participants who were excluded from conditional logistic regression analyses. As stated in the main article, these analyses had little impact on the ranking of <em>P</em> values.</p><p id="__p81" class="p">Additional exploratory analyses of the genome-wide assay genotype data were run for the SNPs listed in Table 3 plus the SNP with the smallest <em>P</em> value (rs11849538). Using conditional logistic regression and adjustment for the eight eigenvectors, we tested SNP-SNP interactions for SNPs residing on different chromosomes (a total of 128 interaction tests). None of these results approached statistical significance (smallest uncorrected <em>P</em> = .02). We also tested whether the per-allele odds ratio differed between the two blinded treatment arms (smallest <em>P</em> = .11), or differed between the two blinded celecoxib groups (smallest <em>P</em> = .02). We also tested whether the SNPs reported were associated with the grade of MS-AEs. After adjusting for the eight eigenvectors, the smallest <em>P</em> value over all the SNPs was .09, suggesting that the grade of MS-AE was not associated with any of the SNPs. Finally, to evaluate whether the time to the first MS-AE was associated with any of the SNPs, we analyzed cases only, using time to first MS-AE as the outcome variable in a Cox regression model. After adjusting for the eight eigenvectors, the smallest <em>P</em> value over all the SNPs was .04. In summary, none of these exploratory analyses provided small enough <em>P</em> values to be robustly statistically significant after adjusting for the post hoc multiple testing.</p><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--><div class="fig  anchored whole_rhythm" id="FA1"><h3>Fig A1.</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717725527760" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650005.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650005.jpg"></a></div><div id="largeobj_idm139717725527760" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3020700/figure/FA1/?report=objectonly">Open in a separate window</a></div><!--caption a7--><div class="caption"><p id="__p82">Quantile-quantile plot of Hardy-Weinberg equilibrium (HWE) exact <em>P</em> values among controls. The gray area represents point-wise 95% CIs for the null distribution of HWE.</p></div></div><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--><div class="fig  anchored whole_rhythm" id="FA2"><h3>Fig A2.</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717714177600" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650006.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650006.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650006.jpg"></a></div><div id="largeobj_idm139717714177600" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3020700/figure/FA2/?report=objectonly">Open in a separate window</a></div><!--caption a7--><div class="caption"><p id="__p83">Quantile-quantile plots of <em>P</em> values from conditional logistic regression analyses, unadjusted (A) and adjusted (B) for eight eigenvectors. The gray area represents point-wise CIs for the null distribution of no association.</p></div></div><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--><div class="fig  anchored whole_rhythm" id="FA3"><h3>Fig A3.</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139717755952912" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3020700_zlj9991004650007.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zlj9991004650007.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3020700/bin/zlj9991004650007.jpg"></a></div><div id="largeobj_idm139717755952912" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3020700/figure/FA3/?report=objectonly">Open in a separate window</a></div><!--caption a7--><div class="caption"><p id="__p84">Electrophoretic mobility shift assays using nuclear extract from lymphoblastoid cell lines for (A) rs7158782, (B) rs7159713, (C) rs11849538, and (D) chromatin immunoprecipitation assays for rs7158782 using GATA-1 antibody (Ab). The circled areas highlight the band associated with GATA-1 binding (wild-type [WT] and WT/variant [V]) as well as the lack of that band for the V sequence.</p></div></div></div></div></div><div id="idm139717716002000" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139717716002000title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139717716001872"></p><p id="__p44" class="p p-first-last">See accompanying editorial on page <a href="//dx.doi.org/10.1200%2FJCO.2010.31.2926" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">4665</a></p><p></p><p class="fn sec" id="idm139717715999552"></p><p id="__p45" class="p p-first-last">Supported in part by National Institutes of Health (NIH) Grants No. U01GM61388, U01GM63173, P50CA116201, and U10CA77202; by Grant No. CCS 015469 from the Canadian Cancer Society; and by the Biobank Japan Project funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology; the Breast Cancer Research Foundation, New York, NY; and the NIH Pharmacogenomics Research Network–RIKEN Center for Genomic Medicine Global Alliance, Pfizer supported the clinical trial from which the patients in this study were obtained.</p><p></p><p class="fn sec" id="idm139717797024240"></p><p id="__p46" class="p p-first-last">Presented in part at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX.</p><p></p><p class="fn sec" id="idm139717797023248"></p><p id="__p47" class="p p-first-last">Terms in blue are defined in the glossary, found at the end of this article and online at <a href="http://www.jco.org" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">www.jco.org</a>.</p><p></p><p class="fn sec" id="idm139717797021168"> </p><p id="__p48" class="p p-first-last">Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.</p><p></p></div></div><div id="__sec25" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec25title">AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</h2><!--/article/back/sec/--><p id="__p50" class="p p-first">Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.</p><p id="__p51" class="p p-last"><strong>Employment or Leadership Position:</strong> None <strong>Consultant or Advisory Role:</strong> James N. Ingle, Pfizer (U); Vered Stearns, Otsuka America Pharmaceuticals (C); Kathleen I. Pritchard, Novartis (C), Pfizer (C), Roche (C) <strong>Stock Ownership:</strong> None <strong>Honoraria:</strong> Matthew J. Ellis, AstraZeneca, Pfizer; Vered Stearns, AstraZeneca; Kathleen I. Pritchard, Novartis, Pfizer, Roche <strong>Research Funding:</strong> Matthew J. Ellis, AstraZeneca; Vered Stearns, Novartis, Pfizer <strong>Expert Testimony:</strong> Kathleen I. Pritchard, AstraZeneca (C), Novartis (C) <strong>Other Remuneration:</strong> None</p></div><div id="__sec26" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec26title">AUTHOR CONTRIBUTIONS</h2><!--/article/back/sec/--><p id="__p52" class="p p-first"><strong>Conception and design:</strong> James N. Ingle, Daniel J. Schaid, Paul E. Goss, Mohan Liu, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Joseph Pater, Liewei Wang, Vered Stearns, David A. Flockhart, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p53"><strong>Financial support:</strong> James N. Ingle, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p54"><strong>Administrative support:</strong> James N. Ingle, Taisei Mushiroda, Joseph Pater, Richard M. Weinshilboum</p><p id="__p55"><strong>Provision of study materials or patients:</strong> James N. Ingle, Paul E. Goss, Mohan Liu, Judy-Anne W. Chapman, Michiaki Kubo, Lois Shepherd, Daniel C. Rohrer, Matthew P. Goetz, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p56"><strong>Collection and assembly of data:</strong> James N. Ingle, Paul E. Goss, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Gregory D. Jenkins, Anthony Batzler, Lois Shepherd, Joseph Pater, Matthew J. Ellis, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p57"><strong>Data analysis and interpretation:</strong> James N. Ingle, Daniel J. Schaid, Paul E. Goss, Mohan Liu, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Gregory D. Jenkins, Anthony Batzler, Liewei Wang, Matthew P. Goetz, Kathleen I. Pritchard, David A. Flockhart, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p58"><strong>Manuscript writing:</strong> James N. Ingle, Daniel J. Schaid, Paul E. Goss, Mohan Liu, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Gregory D. Jenkins, Anthony Batzler, Lois Shepherd, Joseph Pater, Liewei Wang, Matthew J. Ellis, Vered Stearns, Daniel C. Rohrer, Matthew P. Goetz, Kathleen I. Pritchard, David A. Flockhart, Yusuke Nakamura, Richard M. Weinshilboum</p><p id="__p59" class="p p-last"><strong>Final approval of manuscript:</strong> James N. Ingle, Daniel J. Schaid, Paul E. Goss, Mohan Liu, Taisei Mushiroda, Judy-Anne W. Chapman, Michiaki Kubo, Gregory D. Jenkins, Anthony Batzler, Lois Shepherd, Joseph Pater, Liewei Wang, Matthew J. Ellis, Vered Stearns, Daniel C. Rohrer, Matthew P. Goetz, Kathleen I. Pritchard, David A. Flockhart, Yusuke Nakamura, Richard M. Weinshilboum</p></div><div id="idm139717725684512" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139717725684512title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="element-citation">Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Forbes JF, Cuzick J, et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <span><span class="ref-journal">Lancet Oncol. </span>2008;<span class="ref-vol">9</span>:45–53.</span> [<a href="/pubmed/18083636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Effect+of+anastrozole+and+tamoxifen+as+adjuvant+treatment+for+early-stage+breast+cancer:+100-month+analysis+of+the+ATAC+trial&amp;author=JF+Forbes&amp;author=J+Cuzick&amp;volume=9&amp;publication_year=2008&amp;pages=45-53&amp;pmid=18083636&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="element-citation">Coates AS, Keshaviah A, Thürlimann B, et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:486–492.</span> [<a href="/pubmed/17200148" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Five+years+of+letrozole+compared+with+tamoxifen+as+initial+adjuvant+therapy+for+postmenopausal+women+with+endocrine-responsive+early+breast+cancer:+Update+of+study+BIG+1-98&amp;author=AS+Coates&amp;author=A+Keshaviah&amp;author=B+Thürlimann&amp;volume=25&amp;publication_year=2007&amp;pages=486-492&amp;pmid=17200148&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="element-citation">Coombes RC, Kilburn LS, Snowdon CF, et al.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. <span><span class="ref-journal">Lancet. </span>2007;<span class="ref-vol">369</span>:559–570.</span> [<a href="/pubmed/17307102" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Survival+and+safety+of+exemestane+versus+tamoxifen+after+2-3+years'+tamoxifen+treatment+(Intergroup+Exemestane+Study):+A+randomised+controlled+trial&amp;author=RC+Coombes&amp;author=LS+Kilburn&amp;author=CF+Snowdon&amp;volume=369&amp;publication_year=2007&amp;pages=559-570&amp;pmid=17307102&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="element-citation">Jakesz R, Jonat W, Gnant M, et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. <span><span class="ref-journal">Lancet. </span>2005;<span class="ref-vol">366</span>:455–462.</span> [<a href="/pubmed/16084253" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Switching+of+postmenopausal+women+with+endocrine-responsive+early+breast+cancer+to+anastrozole+after+2+years'+adjuvant+tamoxifen:+Combined+results+of+ABCSG+trial+8+and+ARNO+95+trial&amp;author=R+Jakesz&amp;author=W+Jonat&amp;author=M+Gnant&amp;volume=366&amp;publication_year=2005&amp;pages=455-462&amp;pmid=16084253&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="element-citation">Boccardo F, Rubagotti A, Guglielmini P, et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Updated results of the Italian tamoxifen anastrozole (ITA) trial. <span><span class="ref-journal">Ann Oncol. </span>2006;<span class="ref-vol">17</span>(suppl 7):vii10–vii14.</span> [<a href="/pubmed/16760270" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&amp;title=Switching+to+anastrozole+versus+continued+tamoxifen+treatment+of+early+breast+cancer:+Updated+results+of+the+Italian+tamoxifen+anastrozole+(ITA)+trial&amp;author=F+Boccardo&amp;author=A+Rubagotti&amp;author=P+Guglielmini&amp;volume=17&amp;issue=suppl+7&amp;publication_year=2006&amp;pages=vii10-vii14&amp;pmid=16760270&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="element-citation">Kaufmann M, Jonat W, Hilfrich J, et al.  Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:2664–2670.</span> [<a href="/pubmed/17563395" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Improved+overall+survival+in+postmenopausal+women+with+early+breast+cancer+after+anastrozole+initiated+after+treatment+with+tamoxifen+compared+with+continued+tamoxifen:+The+ARNO+95+study&amp;author=M+Kaufmann&amp;author=W+Jonat&amp;author=J+Hilfrich&amp;volume=25&amp;publication_year=2007&amp;pages=2664-2670&amp;pmid=17563395&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="element-citation">Goss PE, Ingle JN, Martino S, et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. <span><span class="ref-journal">J Natl Cancer Inst. </span>2005;<span class="ref-vol">97</span>:1262–1271.</span> [<a href="/pubmed/16145047" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Natl+Cancer+Inst&amp;title=Randomized+trial+of+letrozole+following+tamoxifen+as+extended+adjuvant+therapy+in+receptor-positive+breast+cancer:+Updated+findings+from+NCIC+CTG+MA.17&amp;author=PE+Goss&amp;author=JN+Ingle&amp;author=S+Martino&amp;volume=97&amp;publication_year=2005&amp;pages=1262-1271&amp;pmid=16145047&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="element-citation">Mamounas EP, Jeong JH, Wickerham DL, et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:1965–1971.</span> [<a href="/pubmed/18332472" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Benefit+from+exemestane+as+extended+adjuvant+therapy+after+5+years+of+adjuvant+tamoxifen:+Intention-to-treat+analysis+of+the+National+Surgical+Adjuvant+Breast+and+Bowel+Project+B-33+trial&amp;author=EP+Mamounas&amp;author=JH+Jeong&amp;author=DL+Wickerham&amp;volume=26&amp;publication_year=2008&amp;pages=1965-1971&amp;pmid=18332472&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="element-citation">Winer EP, Hudis C, Burstein HJ, et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. <span><span class="ref-journal">J Clin Oncol. </span>2005;<span class="ref-vol">23</span>:619–629.</span> [<a href="/pubmed/15545664" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=American+Society+of+Clinical+Oncology+technology+assessment+on+the+use+of+aromatase+inhibitors+as+adjuvant+therapy+for+postmenopausal+women+with+hormone+receptor-positive+breast+cancer:+Status+report+2004&amp;author=EP+Winer&amp;author=C+Hudis&amp;author=HJ+Burstein&amp;volume=23&amp;publication_year=2005&amp;pages=619-629&amp;pmid=15545664&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="element-citation">Partridge AH, LaFountain A, Mayer E, et al.  Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:556–562.</span> [<a href="/pubmed/18180462" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Adherence+to+initial+adjuvant+anastrozole+therapy+among+women+with+early-stage+breast+cancer&amp;author=AH+Partridge&amp;author=A+LaFountain&amp;author=E+Mayer&amp;volume=26&amp;publication_year=2008&amp;pages=556-562&amp;pmid=18180462&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="element-citation">Crew KD, Greenlee H, Capodice J, et al.  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:3877–3883.</span> [<a href="/pubmed/17761973" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Prevalence+of+joint+symptoms+in+postmenopausal+women+taking+aromatase+inhibitors+for+early-stage+breast+cancer&amp;author=KD+Crew&amp;author=H+Greenlee&amp;author=J+Capodice&amp;volume=25&amp;publication_year=2007&amp;pages=3877-3883&amp;pmid=17761973&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="element-citation">Henry NL, Giles JT, Ang D, et al.  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2008;<span class="ref-vol">111</span>:365–372.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3081690/">PMC free article</a>]</span> [<a href="/pubmed/17922185" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Prospective+characterization+of+musculoskeletal+symptoms+in+early+stage+breast+cancer+patients+treated+with+aromatase+inhibitors&amp;author=NL+Henry&amp;author=JT+Giles&amp;author=D+Ang&amp;volume=111&amp;publication_year=2008&amp;pages=365-372&amp;pmid=17922185&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="element-citation">Pearson TA, Manolio TA. How to interpret a genome-wide association study. <span><span class="ref-journal">JAMA. </span>2008;<span class="ref-vol">299</span>:1335–1344.</span> [<a href="/pubmed/18349094" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=How+to+interpret+a+genome-wide+association+study&amp;author=TA+Pearson&amp;author=TA+Manolio&amp;volume=299&amp;publication_year=2008&amp;pages=1335-1344&amp;pmid=18349094&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="element-citation">Solomon SD, McMurray JJ, Pfeffer MA, et al.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:1071–1080.</span> [<a href="/pubmed/15713944" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Cardiovascular+risk+associated+with+celecoxib+in+a+clinical+trial+for+colorectal+adenoma+prevention&amp;author=SD+Solomon&amp;author=JJ+McMurray&amp;author=MA+Pfeffer&amp;volume=352&amp;publication_year=2005&amp;pages=1071-1080&amp;pmid=15713944&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="element-citation">Rosenbaum PR. Optimal matching for observational studies. <span><span class="ref-journal">J Am Stat Assoc. </span>1989;<span class="ref-vol">84</span>:1024–1032.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Stat+Assoc&amp;title=Optimal+matching+for+observational+studies&amp;author=PR+Rosenbaum&amp;volume=84&amp;publication_year=1989&amp;pages=1024-1032&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="element-citation">Patterson N, Price AL, Reich D. Population structure and eigenanalysis. <span><span class="ref-journal">PLoS Genet. </span>2006;<span class="ref-vol">2</span>:e190.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1713260/">PMC free article</a>]</span> [<a href="/pubmed/17194218" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genet&amp;title=Population+structure+and+eigenanalysis&amp;author=N+Patterson&amp;author=AL+Price&amp;author=D+Reich&amp;volume=2&amp;publication_year=2006&amp;pages=e190&amp;pmid=17194218&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="element-citation">Price AL, Patterson NJ, Plenge RM, et al.  Principal components analysis corrects for stratification in genome-wide association studies. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:904–909.</span> [<a href="/pubmed/16862161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Principal+components+analysis+corrects+for+stratification+in+genome-wide+association+studies&amp;author=AL+Price&amp;author=NJ+Patterson&amp;author=RM+Plenge&amp;volume=38&amp;publication_year=2006&amp;pages=904-909&amp;pmid=16862161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="element-citation">Purcell S, Neale B, Todd-Brown K, et al.  PLINK: A tool set for whole-genome association and population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:559–575.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+A+tool+set+for+whole-genome+association+and+population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;volume=81&amp;publication_year=2007&amp;pages=559-575&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="element-citation">Li Y, Willer CJ, Sanna S, et al.  Genotype imputation. <span><span class="ref-journal">Annu Rev Genomics Hum Genet. </span>2009;<span class="ref-vol">10</span>:387–406.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2925172/">PMC free article</a>]</span> [<a href="/pubmed/19715440" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Genomics+Hum+Genet&amp;title=Genotype+imputation&amp;author=Y+Li&amp;author=CJ+Willer&amp;author=S+Sanna&amp;volume=10&amp;publication_year=2009&amp;pages=387-406&amp;pmid=19715440&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="element-citation">Tian C, Gregersen PK, Seldin MF. Accounting for ancestry: Population substructure and genome-wide association studies. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:R143–R150.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2782357/">PMC free article</a>]</span> [<a href="/pubmed/18852203" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mol+Genet&amp;title=Accounting+for+ancestry:+Population+substructure+and+genome-wide+association+studies&amp;author=C+Tian&amp;author=PK+Gregersen&amp;author=MF+Seldin&amp;volume=17&amp;publication_year=2008&amp;pages=R143-R150&amp;pmid=18852203&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="element-citation">Tian C, Plenge R, Ransom M, et al.  Analysis and application of European genetic substructure using 300 K SNP information. <span><span class="ref-journal">PLoS Genetics. </span>2008;<span class="ref-vol">4</span>:29–39.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2211544/">PMC free article</a>]</span> [<a href="/pubmed/18208329" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genetics&amp;title=Analysis+and+application+of+European+genetic+substructure+using+300+K+SNP+information&amp;author=C+Tian&amp;author=R+Plenge&amp;author=M+Ransom&amp;volume=4&amp;publication_year=2008&amp;pages=29-39&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="element-citation">Yu K, Wang Z, Li Q, et al.  Population substructure and control selection in genome-wide association studies. <span><span class="ref-journal">PLoS One. </span>2008;<span class="ref-vol">3</span>:e2551.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2432498/">PMC free article</a>]</span> [<a href="/pubmed/18596976" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Population+substructure+and+control+selection+in+genome-wide+association+studies&amp;author=K+Yu&amp;author=Z+Wang&amp;author=Q+Li&amp;volume=3&amp;publication_year=2008&amp;pages=e2551&amp;pmid=18596976&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="element-citation">Devlin B, Roeder K. 1999. Genomic control for association studies. <span><span class="ref-journal">Biometrics. </span>1999;<span class="ref-vol">55</span>:997–1004.</span> [<a href="/pubmed/11315092" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biometrics&amp;title=1999.+Genomic+control+for+association+studies&amp;author=B+Devlin&amp;author=K+Roeder&amp;volume=55&amp;publication_year=1999&amp;pages=997-1004&amp;pmid=11315092&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="element-citation">Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>:888–898.</span> [<a href="/pubmed/19710487" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Interleukin-17+and+type+17+helper+T+cells&amp;author=P+Miossec&amp;author=T+Korn&amp;author=VK+Kuchroo&amp;volume=361&amp;publication_year=2009&amp;pages=888-898&amp;pmid=19710487&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="element-citation">Kopec JA, Esdaile JM. Bias in case-control studies: A review. <span><span class="ref-journal">J Epidemiol Community Health. </span>1990;<span class="ref-vol">44</span>:179–186.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1060638/">PMC free article</a>]</span> [<a href="/pubmed/2273353" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Epidemiol+Community+Health&amp;title=Bias+in+case-control+studies:+A+review&amp;author=JA+Kopec&amp;author=JM+Esdaile&amp;volume=44&amp;publication_year=1990&amp;pages=179-186&amp;pmid=2273353&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">26. <span class="element-citation">Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. <span><span class="ref-journal">Annu Rev Med. </span>2009;<span class="ref-vol">60</span>:443–456.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2717504/">PMC free article</a>]</span> [<a href="/pubmed/19630580" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Med&amp;title=The+HapMap+and+genome-wide+association+studies+in+diagnosis+and+therapy&amp;author=TA+Manolio&amp;author=FS+Collins&amp;volume=60&amp;publication_year=2009&amp;pages=443-456&amp;pmid=19630580&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">27. <span class="element-citation">Pekarsky Y, Hallas C, Croce CM. The role of <em>TCL1</em> in human T-cell leukemia. <span><span class="ref-journal">Oncogene. </span>2001;<span class="ref-vol">20</span>:5638–5643.</span> [<a href="/pubmed/11607815" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+role+of+TCL1+in+human+T-cell+leukemia&amp;author=Y+Pekarsky&amp;author=C+Hallas&amp;author=CM+Croce&amp;volume=20&amp;publication_year=2001&amp;pages=5638-5643&amp;pmid=11607815&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">28. <span class="element-citation">Noguchi M, Ropars V, Roumestand C, et al.  Proto-oncogene TCL1: More than just a coactivator for Akt. <span><span class="ref-journal">FASEB J. </span>2007;<span class="ref-vol">21</span>:2273–2284.</span> [<a href="/pubmed/17360849" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J&amp;title=Proto-oncogene+TCL1:+More+than+just+a+coactivator+for+Akt&amp;author=M+Noguchi&amp;author=V+Ropars&amp;author=C+Roumestand&amp;volume=21&amp;publication_year=2007&amp;pages=2273-2284&amp;pmid=17360849&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">29. <span class="element-citation">Cecil RL, Archer BH. Arthritis of the menopause. <span><span class="ref-journal">JAMA. </span>1925;<span class="ref-vol">84</span>:75–79.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Arthritis+of+the+menopause&amp;author=RL+Cecil&amp;author=BH+Archer&amp;volume=84&amp;publication_year=1925&amp;pages=75-79&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">30. <span class="element-citation">Chlebowski RT, Johnson KC, Kooperberg C, et al.  The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. <span><span class="ref-journal">J Clin Oncol. </span>2006;<span class="ref-vol">24</span>(suppl; abstr LBA):2s.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=The+Women's+Health+Initiative+randomized+trial+of+calcium+plus+vitamin+D:+Effects+on+breast+cancer+and+arthralgias&amp;author=RT+Chlebowski&amp;author=KC+Johnson&amp;author=C+Kooperberg&amp;volume=24&amp;issue=suppl;+abstr+LBA&amp;publication_year=2006&amp;pages=2s&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3020700&amp;issue-id=193293&amp;journal-id=660&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#idm139717723262560title">Abstract</a></li><li><a href="#__sec5title">INTRODUCTION</a></li><li><a href="#__sec6title">PATIENTS AND METHODS</a></li><li><a href="#__sec15title">RESULTS</a></li><li><a href="#__sec24title">DISCUSSION</a></li><li><a href="#idm139717718861280title">Acknowledgment</a></li><li><a href="#idm139717724184432title">Glossary Terms</a></li><li><a href="#app1title">Appendix</a></li><li><a href="#idm139717716002000title">Footnotes</a></li><li><a href="#__sec25title">AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</a></li><li><a href="#__sec26title">AUTHOR CONTRIBUTIONS</a></li><li><a href="#idm139717725684512title">REFERENCES</a></li></ul></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr>Articles from <span class="acknowledgment-journal-title">Journal of Clinical Oncology</span> are provided here courtesy of <strong>American Society of Clinical Oncology</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC3020700/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC3020700/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC3020700/pdf/zlj4674.pdf">PDF (1.9M)</a></li> | <li><a href="#" data-citationid="PMC3020700" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3020700%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3020700%2F&amp;text=Genome-Wide%20Associations%20and%20Functional%20Genomic%20Studies%20of%20Musculoskeletal%20Adverse%20Events%20in%20Women%20Receiving%20Aromatase%20Inhibitors" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3020700%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="20876420" data-aiid="3020700" data-aid="3020700" data-iid="193293" data-domainid="660" data-domain="jco" data-accid="PMC3020700" data-md5="c1b760c4558bcfce8a183f532aaf2185"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T05:59:45-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal101&amp;ncbi_phid=CE88993EDD516BD10000000003B9025C&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3020700%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=jco&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC3020700/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>